SCHEMBL3344553

SCHEMBL3344553

CC(=O)C(C(=O)O)c1ccc2ncccc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.51
AKR1C2 P52895 1/20 0.51
ALDH1A1 P00352 4/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
LMNA P02545 1/20 0.49
HTT P42858 2/20 0.48
ALOX15 P16050 1/20 0.48
PLK1 P53350 1/20 0.48
NPC1 O15118 3/20 0.47
POLB P06746 3/20 0.47
MAPT P10636 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
NR3C1 P04150 1/20 0.45
RAB9A P51151 2/20 0.45
MCL1 Q07820 1/20 0.45
PABPC1 P11940 1/20 0.45
ACACB O00763 1/20 0.44
MET P08581 2/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19926229 0.85 ALOX15 (0.55) AKR1C3AKR1C2ALDH1A1SMN1; SMN2LMNA
SCHEMBL2341919 0.82 AKR1C3 (0.70) AKR1C3AKR1C2ALDH1A1SMN1; SMN2LMNA
SCHEMBL30564458 0.82 AKR1C3 (0.70) AKR1C3AKR1C2ALDH1A1SMN1; SMN2LMNA
SCHEMBL1492942 0.82 AKR1C3 (0.70) AKR1C3AKR1C2ALDH1A1SMN1; SMN2LMNA
SCHEMBL28359064 0.81 ALDH1A1 (0.51) AKR1C3AKR1C2ALDH1A1SMN1; SMN2LMNA
SCHEMBL28301104 0.81 OGA (0.42) ALDH1A1SMN1; SMN2NPC1MAPTKMT2A
SCHEMBL19926091 0.79 ALOX15 (0.58) AKR1C3AKR1C2ALDH1A1SMN1; SMN2LMNA
SCHEMBL10631845 0.79 AKR1C3 (0.50) AKR1C3AKR1C2ALDH1A1SMN1; SMN2LMNA
SCHEMBL14320091 0.79 AKR1C3 (0.53) AKR1C3AKR1C2ALDH1A1SMN1; SMN2LMNA
SCHEMBL2699086 0.79 AKR1C3 (0.53) AKR1C3AKR1C2ALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105681-A1 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS LASSOIE MARIE-AGNES 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105681-A1 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS SCN4A, NECTIN4, VPS4B AKR1C3 3560/4885AKR1C2 3238/4885ALDH1A1 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.